Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31430877 | 0.81 | KMT2A (0.37) | PDXKPLAUKMT2AHTTMEN1 | |
| SCHEMBL5046239 | 0.81 | KMT2A (0.35) | PDXKPLAUKMT2AHTTMEN1 | |
| SCHEMBL856508 | 0.81 | KMT2A (0.37) | PDXKPLAUKMT2AHTTMEN1 | |
| SCHEMBL25233643 | 0.79 | ALDH1A1 (0.39) | PLAUKMT2AHTTMAPTKDM4E | |
| SCHEMBL15052847 | 0.79 | HTT (0.34) | PLAUKMT2AHTTMEN1MAPT | |
| SCHEMBL15052641 | 0.79 | CCR5 (0.42) | PLAUKMT2AHTT | |
| SCHEMBL10325290 | 0.78 | PDXK (0.48) | PDXKPLAUARMAPTHPGD | |
| SCHEMBL30058522 | 0.78 | PDXK (0.48) | PDXKPLAUARMAPTHPGD | |
| SCHEMBL24502939 | 0.78 | KMT2A (0.41) | PDXKOPRK1PTGDR2PLAUKMT2A | |
| Hydrochloric Acid SCHEMBL16635240 | 0.78 | CCR5 (0.41) | PLAUKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| CN-101243083-A | Naphthyridine compounds | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | HRH3, HRH4, HRH1 | PDXK 1415/4885OPRK1 169/4885PTGDR2 633/4885 |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | PDXK 2782/4885OPRK1 4711/4885PTGDR2 3064/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | PDXK 2782/4885OPRK1 4711/4885PTGDR2 3064/4885 |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | CCR5, MSR1, CCR2 | PDXK 4098/4885OPRK1 980/4885PTGDR2 1264/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | PDXK 111/4885OPRK1 2479/4885PTGDR2 1013/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PDXK 550/4885OPRK1 3553/4885PTGDR2 4195/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | PDXK 1637/4885OPRK1 3461/4885PTGDR2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.